Bevicra 100 mg Injection 4 ml is a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Cancer can start in one region of the body and spread to other parts. This is referred to as metastasis.

Bevicra 100 mg Injection 4 ml contains 'Bevacizumab' that works against vascular endothelial growth factor (VEGF) which is found on the lining of lymph and blood vessels. VEGF causes blood vessels to grow within tumours which provide oxygen and nutrients to the tumour. Inhibition of vascular endothelial growth factor limits the flow of oxygen and nutrients to the tumour, causing it to shrink or cease developing. Thus, it helps treat cancers.

Bevicra 100 mg Injection 4 ml will be administered by a healthcare professional; do not self-administer. Based on your medical condition, your doctor will decide the dose and duration. In some cases, Bevicra 100 mg Injection 4 ml may cause loss of appetite, constipation, fever, nosebleeds, change in speech, and taste. The majority of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen

Avoid taking Bevicra 100 mg Injection 4 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bevicra 100 mg Injection 4 ml may cause sleepiness and fainting, so avoid driving while on treatment with Bevicra 100 mg Injection 4 ml. Do not breastfeed during the treatment and for 6months after the last dose of Bevicra 100 mg Injection 4 ml. Keep your doctor informed about your health condition and all the medicines you take to rule out any side effects.

Bevicra 100 mg Injection 4 ml contains Bevacizumab, a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, cancer of colon and rectum. Bevicra 100 mg Injection 4 ml works against a protein called vascular endothelial growth factor (VEGF). Vascular endothelial growth factor (VEGF) inhibition limits the flow of oxygen and nutrients to the tumour cells, causing them to shrink or cease developing. Thus, it helps treat cancer.

Bevicra 100 mg Injection 4 ml should only be taken under medical supervision. While taking Bevicra 100 mg Injection 4 ml, the doctor will monitor your condition on a regular basis. If you have a history of allergic reactions to Bevicra 100 mg Injection 4 ml or other medications, inform your doctor before taking it. Avoid taking Bevicra 100 mg Injection 4 ml if you are pregnant. Use effective contraception during the treatment and for 6months after the last dose. Bevicra 100 mg Injection 4 ml may cause sleepiness and fainting, so avoid driving while on treatment with Bevicra 100 mg Injection 4 ml. Inform your doctor if you have/had high blood pressure, heart attack, stroke, bleeding problems, stomach/intestinal bleeding, perforation; if you had surgery in the past 28days/are due to have surgery. Do not breastfeed during the treatment and for 6months after the last dose of Bevicra 100 mg Injection 4 ml. While taking Bevicra 100 mg Injection 4 ml, please do not get any immunizations or vaccinations unless your doctor has approved it. Bevicra 100 mg Injection 4 ml may increase the risk of bleeding, so be cautious and consult your doctor if you notice any bleeding or bruising.